Black Diamond Therapeutics (BDTX) Enterprise Value (2018 - 2025)
Black Diamond Therapeutics' Enterprise Value history spans 6 years, with the latest figure at -$128.7 million for Q4 2025.
- For Q4 2025, Enterprise Value fell 30.51% year-over-year to -$128.7 million; the TTM value through Dec 2025 reached -$128.7 million, down 30.51%, while the annual FY2025 figure was -$128.7 million, 30.51% down from the prior year.
- Enterprise Value reached -$128.7 million in Q4 2025 per BDTX's latest filing, up from -$135.5 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$98.6 million in Q4 2024 to a low of -$290.1 million in Q1 2021.
- Average Enterprise Value over 3 years is -$163.4 million, with a median of -$135.5 million recorded in 2025.
- Peak YoY movement for Enterprise Value: rose 29.44% in 2021, then crashed 32.29% in 2025.
- A 3-year view of Enterprise Value shows it stood at -$235.0 million in 2021, then soared by 58.05% to -$98.6 million in 2024, then tumbled by 30.51% to -$128.7 million in 2025.
- Per Business Quant, the three most recent readings for BDTX's Enterprise Value are -$128.7 million (Q4 2025), -$135.5 million (Q3 2025), and -$142.8 million (Q2 2025).